Covalent inhibitors are experiencing a growing resurgence in drug design and are an
increasingly useful tool in molecular biology. The ability to attach inhibitors to their targets by …

Gram-negative pathogens expressing serine β-lactamases (SBLs) and metallo-β-
lactamases (MBLs), especially those with carbapenemase activity, threaten the clinical utility …

The divergent sequences, protein structures, and catalytic mechanisms of serine-and
metallo-β-lactamases hamper the development of wide-spectrum β-lactamase inhibitors that …

Serine and metallo-carbapenemases are a serious health concern due to their capability to
hydrolyze nearly all β-lactam antibiotics. However, the molecular basis for their unique …

We use mass spectrometry (MS), under denaturing and non-denaturing solution conditions,
along with ultraviolet photodissociation (UVPD) to characterize structural variations in New …

Aberrant protein citrullination is associated with many pathologies; however, the specific
effects of this modification remain unknown. We have previously demonstrated that serine …

To counter the emergence of β-lactamase (BL) mediated resistance, design of new β-
lactamase inhibitors (BLIs) is critical. Many high-resolution crystallographic structures of BL …

There have been many concepts (catalytic mechanism-based and substratebased designs,
etc.) whose exploitation has been demonstrated to be able to quickly and cost-effectively …

Class C β-lactamases have previously been shown to be efficiently inactivated by O-
aryloxycarbonyl hydroxamates. O-Phenoxycarbonyl-N-benzyloxycarbonylhydroxylamine (1) …

O-Aryloxycarbonyl hydroxamates have previously been shown to covalently inactivate
serine/amine amidohydrolases such as class C β-lactamases and a N-terminal hydrolase …